Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Urothelial Cancer/Enfortumab Vedotin

Jonathan Rosenberg

MD

🏢Memorial Sloan Kettering Cancer Center🌐USA

Chief, GU Oncology Service

78
h-index
0
Key Papers
0
Key Contributions

👥Biography 个人简介

Jonathan Rosenberg is a leading bladder cancer investigator who has been pivotal in the clinical development of enfortumab vedotin and erdafitinib. He led the EV-301 trial demonstrating enfortumab vedotin superiority over chemotherapy in previously treated urothelial cancer. His molecular profiling studies have advanced understanding of bladder cancer heterogeneity.

Share:

🧪Research Fields 研究领域

Urothelial cancer
Enfortumab vedotin
Erdafitinib
FGFR-targeted therapy
Molecular subtypes

🎓Key Contributions 主要贡献

Representative Works 代表性著作

📄Data Sources 数据来源

Last updated: 2026-04-01 | All information from publicly available academic sources

关注 Jonathan Rosenberg 的研究动态

Follow Jonathan Rosenberg's research updates

留下邮箱,当我们发布与 Jonathan Rosenberg(Memorial Sloan Kettering Cancer Center)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment